Erlotinib Suppliers & Bulk Manufacturers

Available Forms: Oral Tablets

Available Strengths: 25 mg, 100 mg, 150 mg

Reference Brands: Tarceva® (US & EU)

Category: Oncology Cancer Care

Erlotinib is a targeted oral therapy for NSCLC and pancreatic cancer, available as 25 mg, 100 mg, and 150 mg tablets in the US and EU under Tarceva® and generics. Erlotinib is available in Oral Tablets and strengths such as 25 mg, 100 mg, 150 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Erlotinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Erlotinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Erlotinib Tablets are a targeted oncology treatment used in the EU and US, primarily indicated for non-small cell lung cancer (NSCLC) with EGFR mutations and advanced pancreatic cancer. As a tyrosine kinase inhibitor (TKI), Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR), slowing cancer cell proliferation. Available in 25 mg, 100 mg, and 150 mg strengths, Erlotinib is marketed under the brand name Tarceva® and widely distributed as a generic formulation across global markets. Pharmaceutical distributors and B2B buyers rely on Erlotinib as a high-value, targeted therapy with well-established clinical efficacy in precision oncology.